Model N Unveils First Revenue Management Platform to Enable Digital Reinvention
Model N, Inc. (NYSE: MODN), the leading provider of revenue management solutions for the Pharmaceutical, Medical Device, High Tech, Manufacturing and Semiconductor industries, today announced the release of the next generation of its Revenue Cloud platform. Revenue Cloud now becomes the first end-to-end platform to enable digital reinvention for companies in these industries.
About Digital Reinvention
Digital disruption has already reduced the average tenure for companies on the S&P 500 list from 33 to 12 years, and only 8% of companies believe their business models will remain viable through digitization. Pharmaceutical, Medical Device, High Tech, Manufacturing and Semiconductor companies face a stark choice: reinvent or perish.
Bold digital reinvention strategies begin with placing customers at the center of companies’ digital activity. Instead of seeing themselves through the internal lens of functions, products, and processes, companies now see themselves through the lens of their customers. These strategies require a deep understanding of unique customer segment needs, business models, revenues, and profitability, and more.
Companies that embark on digital reinvention strategies must do the following:
- Redefine the business they are in
- Redefine who their customers are
- Reinvent their offerings to those customers
- Delight customers in each interaction
- Position themselves in the digital ecosystem
- Realign operations with intelligent internal processes
The Platform for Digital Reinvention
While an offensive platform strategy focused on the demand-side is proven to yield the best results, only 1.5% percent of companies have adopted one, mainly due to the lack of a Digital Reinvention platform.
Model N Revenue Cloud is the first Digital Reinvention platform, designed specifically for Life Sciences, High Tech and Manufacturing companies.
This release of Revenue Cloud includes the following highlights:
- Introduction of Model N CPQ, the next generation of Configure, Price and Quote, which enables companies to reinvent their offerings and their business models
- Introduction of Model N Channel Cloud, an end-to-end solution to manage the digital ecosystem and omni-channel
- Introduction of Revenue Cloud for Semiconductors and Revenue Cloud for Manufacturing
- New versions of Revenue Cloud for Pharma, Revenue Cloud for MedTech, and Revenue Cloud for High-Tech
Introducing Model N CPQ
Model N CPQ is the end-to-end, enterprise-grade platform that bridges the gap between Salesforce and SAP with robustness, performance and scalability that meet the needs of enterprises.
Model N CPQ enables companies to:
- Reinvent their offering to their customers by configuring solutions that are tailored to unique customer needs that include products, software services, data and other elements.
- Align their business with those of their customers’ by leveraging new models such as subscription, outcome base and risk-sharing among others.
- Delight their customers by digitizing their experience with new capabilities, such as self-service.
- Transform internal operations into intelligence processes with new Intelligent Approvals, guided selling, and business intelligence, cutting the process cycle-time to a bare minimum hence significantly enhancing the customer experience.
- Drive business expansion through digital ecosystems and omni-channel.
- Rapidly deploy and execute digital reinvention strategies by interoperating effectively with SAP and SAP Variant Configurator (VC). Marketing and Sales can now start with SAP VC KMAT models as a foundation for new offerings that are tailored to unique customer needs.
- Understand the profitability of a deal, a contract, customers and customer segments with insights that help them understand thoroughly the economics of their digital strategies. Model N CPQ now quotes based on net-price including rebates, Market Development Funds (MDF), and other incentives, not just gross-price.
“Model N next-generation CPQ enables companies to leverage their SAP and SAP VC infrastructure as a stepping stone for their Digital Reinvention strategy.” said Neeraj Gokhale, SVP and Chief Product Officer at Model N. “Creating a new value proposition for customers and aligning the business models with Model N CPQ is enabling companies to grow their top line.”
Introducing Channel Cloud
Embracing the digital ecosystem and omni-channel are paramount to Digital Reinvention. McKinsey research demonstrated that an emerging set of digital ecosystems could account for more than $60 trillion in revenues by 2025, or more than 30 percent of global corporate revenues. In a world of ecosystems, as industry boundaries blur, strategy needs a much broader frame of reference. Current point channel solutions fall significantly short of meeting the sophistication of the ecosystem.
Model N’s new Channel Cloud enables companies to leverage a wide ecosystem that includes global, multi-tier, sophisticated channels as part of their Digital Reinvention. Channel Cloud combines intelligent processes, visibility, sophisticated rewards to align business models, and a comprehensive data platform.
Channel Cloud enables companies to mesh with the digital ecosystem by:
- Driving their channels’ marketing execution to meet their revenue goals with Market Development Funds (MDF) Management. It is the first MDF solution in a fully integrated end-to-end channel solution.
- Establishing a digital ecosystem for channel collaboration with Channel Management. Companies can maximize revenue by avoiding channel conflict and flawlessly executing with the ecosystem.
- Incenting the channel to drive revenues with Rebate Management. Companies can balance discounting decisions and post-deal rebating based on results to optimize revenues.
- Ensuring a single source of truth with Channel Data Management (CDM), putting the entire digital ecosystem on the same page. CDM delivers real-time, accurate, complete channel data, including sales and inventory, enabling transparency and channel performance.
Channel Cloud is offered as part of Revenue Cloud for High Tech, Revenue Cloud for Semiconductors, Revenue Cloud for Manufacturing, and Revenue Cloud for MedTech.
Revenue Cloud Strengthened
In addition to Model N CPQ and the new Channel Cloud solution, Model N is announcing a completely new Revenue Cloud for Semiconductor and Revenue Cloud for Manufacturing suites, and new versions of its Revenue Cloud for Pharma, Revenue Cloud for MedTech, and Revenue Cloud for High Tech suites, to enable Digital Reinvention in those industries. Full details of each new Revenue Cloud solution are available at www.modeln.com or through the media contact listed below.
For more information on Model N Revenue Cloud, please visit modeln.com/products/revenue-cloud .
About Model N
Model N is the leader in Revenue Management solutions. Driving mission-critical business processes such as configure, price and quote (CPQ), contract and rebate management, business intelligence, and regulatory compliance, Model N solutions transform the revenue lifecycle from a series of disjointed operations into a strategic end-to-end process. With deep industry expertise, Model N supports the complex business needs of the world’s leading brands in life sciences, technology and manufacturing across more than 100 countries, including Johnson & Johnson, AstraZeneca, Novartis, Microchip Technology and ON Semiconductor. For more information, visit www.modeln.com. Model N is a registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
Holly Hagerman, 801-373-7888
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 13:49 | Tiedote
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41 | Tiedote
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42 | Tiedote
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00 | Tiedote
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07 | Tiedote
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme